 abstractthe bcl-2/bcl - xl inhibitor navitoclax has shown promise for the treatment of cancer but on - target toxicities have limited its utility . recently 
 , the generation of selective bcl-2 family inhibitors has enabled a careful dissection of bcl-2 biology , and early work indicates that these molecules have improved therapeutic profiles for the treatment of cancer . 
Disclosure of Potential Conflicts of Interest
Funding